Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study of bevacizumab benefit in metastatic colorectal cancer
ISRCTN97323814Phase 2Completed
- Sponsor
- The Christie
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by The Christie. Primary endpoint: Biomarker prediction of clinical benefit. Started Nov 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ISRCTN97323814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97323814.